Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has won the prestigious Association of Strategic Alliance Professionals (ASAP) award for 2018 along with its alliance partner, MSD.
This is the first time a pharmaceutical company from the Middle East and Africa has won the award. It does highlight the contributions both organizations are providing in alliance management to help create a stronger value proposition for the local patients and the healthcare community.
Jerome Carle, General Manager of Julphar, said, “Winning the prestigious ASAP award is a confirmation that the world is taking notice of the important contribution Julphar is making to the global healthcare market. We take great pride in our partnership with MSD and together we bring value and quality to the healthcare community.
“MSD is a global leader and through our partnership, we are able to exceed expectations, develop and manufacture best-in-class solutions to help meet patients’ needs and make a difference to families in the region. We’re truly honored to be recognized for this award.”
MSD (known as Merck & Co in the US and Canada) is a global healthcare provider and one of the largest pharmaceutical companies in the world. Julphar signed a five-year licensing deal with the company in 2014, giving it exclusive rights to produce, market, distribute and sell certain MSD medicines in the UAE, Kuwait, Bahrain, Oman, Qatar and Iraq.
Mazen Altaruti, AVP & Managing Director for MSD in the GCC, said, “This award represents a great success for the region in terms of alliances and partnerships on a local and global scale. Receiving this award highlights the vital work being done in the healthcare industry by both companies to guarantee access to medicines for patients. We look forward to your continued partnership and powerful impact in 2018 and beyond.”
The 2018 ASAP awards finalists were singled out for their exceptional leadership and contributions and competed in four different categories: Alliance for Corporate Social Responsibility, Alliance Program Excellence, Individual Alliance Excellence, and Innovative Best Alliance Practice.
Winners were announced at an awards ceremony at the 2018 ASAP Global Alliance Summit, “Propelling Partnering for the On-Demand World: New Perspectives + Proven Practices for Collaborative Business,” which was held from 26-28 March in Fort Lauderdale, Florida, USA.
Last month, Julphar announced it had been ranked number one pharmaceutical company in the UAE by IMS Health February 2018 panel, reflecting a strong double digit sales growth versus 2017.
Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 5,000 people and distributes pharmaceutical products to more than 50 countries on five continents.
Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism.
Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia that produce more than a million boxes of medicines a day. In 2012, Julphar became one of the largest producer of Insulin with its UAE-based Biotechnology production unit based.
For more information, visit http://www.julphar.net
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A.
Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.
Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
For more information, visit http://www.msd.com
Chris Goward, Head of Communications, +971582633997